Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|November 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-11-01-2012
  • Volume 21
  • Issue 11

Survey Results of Start-Up Cycle Times

Author(s)Tufts, CSDD

Tufts CSDD

A 2012 study conducted by the Tufts Center for the Study of Drug Development shows that academic centers and hospitals take significantly longer to initiate industry-funded clinical trials. Overall, it takes an AMC or hospital more than one year (12.9 months) on average from the pre-study visit to first patient in (FPI) the clinical trial. This compares with 7.9 months for community-based physician practices to complete the same cycle—nearly a 40% time reduction. The Tufts CSDD study evaluated start-up cycle times for 5,296 investigative sites participating in 105 Phase II and III clinical trials. The largest bottleneck is the time from when the contract is received by the center to the time that the contract is executed. AMCs and hospitals take nearly 73% longer than their for-profit counterparts—4.1 months on average versus 1.1 months. Cycle times from contract execution to site initiation, and from site initiation to FPI for non- and for-profit investigative sites are much closer, suggesting that AMCs and hospitals perform more competitively once they get through their less efficient administrative tasks.

Figure 1

—Tufts Center for the Study of Drug Development, https://csdd.tufts.edu

Articles in this issue

about 14 years ago

Act Cover

about 14 years ago

Act Insert cover

about 14 years ago

Pediatric Drug Development

about 14 years ago

ePRO Industry Growth

about 14 years ago

Generic Drugs Making Waves

about 14 years ago

EMA's Mid-Year Report Merits Scrutiny

Related to this article

© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.